Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Free Cash Flow (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Free Cash Flow for 7 consecutive years, with -$12.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 7.07% year-over-year to -$12.2 million, compared with a TTM value of -$62.1 million through Dec 2025, up 10.29%, and an annual FY2025 reading of -$62.1 million, up 10.29% over the prior year.
  • Free Cash Flow was -$12.2 million for Q4 2025 at aTYR PHARMA, up from -$20.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.8 million in Q1 2023 and bottomed at -$22.4 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$12.3 million, with a median of -$11.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow soared 81.93% in 2023, then tumbled 1119.88% in 2024.
  • Year by year, Free Cash Flow stood at -$8.1 million in 2021, then tumbled by 41.76% to -$11.5 million in 2022, then grew by 3.56% to -$11.1 million in 2023, then fell by 18.76% to -$13.2 million in 2024, then grew by 7.07% to -$12.2 million in 2025.
  • Business Quant data shows Free Cash Flow for ATYR at -$12.2 million in Q4 2025, -$20.5 million in Q3 2025, and -$13.9 million in Q2 2025.